🧬 The Bad Genes Club
- BRCA1/2: Most common; account for ~5-10% of all breast cancers.
- BRCA1: ↑ risk of breast (esp. triple-negative), ovarian, pancreatic, prostate cancer.
- BRCA2: ↑ risk of breast (male & female), ovarian, pancreatic, prostate cancer, melanoma.
- Other Key Genes:
- TP53 (Li-Fraumeni): 📌 SBLA mnemonic: Sarcoma, Breast, Leukemia, Adrenocortical.
- PTEN (Cowden): Breast, thyroid, endometrial cancer; hamartomas.
- STK11 (Peutz-Jeghers): GI polyps, breast, GI, pancreatic cancer.

⭐ All are Autosomal Dominant mutations in tumor suppressor genes. Inheritance of one mutated allele requires a second somatic "hit" for tumorigenesis (Knudson's two-hit hypothesis).
🧬 Pathophysiology - Broken Blueprints
Most syndromes are autosomal dominant, involving germline mutations in tumor suppressor genes (TSGs). Function is lost via Knudson's "two-hit" hypothesis.
⭐ Knudson's Two-Hit Hypothesis: A germline mutation (1st hit) is inherited. A second, somatic mutation (2nd hit) in the remaining normal allele leads to loss of heterozygosity (LOH) and subsequent tumorigenesis.

| Gene | Chromosome | Key Associated Cancers |
|---|---|---|
| BRCA1 | 17q21 | Breast (often triple-negative), Ovarian, Pancreatic, Prostate |
| BRCA2 | 13q12 | Breast (often ER+), Male Breast, Ovarian, Prostate, Melanoma |
| TP53 | 17p13 | Li-Fraumeni: Sarcoma, Breast, Brain, Adrenocortical (SBLA) |
| PTEN | 10q23 | Cowden: Breast, Thyroid (follicular), Endometrial, Hamartomas |
🧬 Clinical Manifestations - Cancer Constellations
- Recognizing the full cancer spectrum is crucial for appropriate screening and management. Each syndrome has a distinct pattern of associated malignancies beyond breast cancer.
| Syndrome | Gene(s) | Key Features & Associated Cancers |
|---|---|---|
| HBOC | BRCA1 | ↑ Ovarian (serous), Pancreatic, Prostate (aggressive). Triple-negative breast cancer common. |
| BRCA2 | ↑ Ovarian, Male Breast, Pancreatic, Prostate, Melanoma. | |
| Li-Fraumeni | TP53 | Sarcomas, Brain tumors, Adrenocortical carcinoma, Leukemia. ⚠️ Avoid radiation therapy. |
| Cowden | PTEN | Thyroid (follicular), Endometrial. Mucocutaneous lesions (trichilemmomas, papillomas). |
| Peutz-Jeghers | STK11 | GI (hamartomatous polyps), Pancreatic, Ovarian (sex-cord). Mucocutaneous pigmentation. |
| Hereditary Diffuse Gastric Cancer | CDH1 | Gastric (diffuse/signet ring), Invasive Lobular Breast Cancer. |
⭐ CDH1 mutations are strongly associated with invasive lobular carcinoma of the breast and diffuse gastric cancer (signet ring cell type). Prophylactic gastrectomy is often recommended.
🛡️ Management - Guardians of the Genome
Management focuses on intensive surveillance and risk-reduction strategies. Decisions are highly individualized based on patient preference, age, and specific mutation.
⭐ Prophylactic bilateral mastectomy reduces breast cancer risk by >95% in BRCA carriers. Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk by ~80% and also lowers breast cancer risk by ~50%.
⚡ High-Yield Points - Biggest Takeaways
- BRCA1/2 are the most common (autosomal dominant) causes of hereditary breast and ovarian cancer.
- BRCA1 is strongly associated with triple-negative breast cancer; BRCA2 with male breast cancer.
- Li-Fraumeni (TP53): Sarcoma, Breast cancer, Leukemia, Adrenocortical carcinoma (SBLA).
- Cowden syndrome (PTEN): Hamartomas, macrocephaly; risk for breast, thyroid, endometrial cancer.
- Peutz-Jeghers (STK11): Mucocutaneous pigmentation, GI polyps, increased breast cancer risk.
- ATM gene mutations (Ataxia-Telangiectasia) also confer an increased breast cancer risk.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app